

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

AN ACT

RELATING TO PHARMACIES; PROVIDING FOR CHANGES TO THE PHARMACY
AUDIT PROCESS; EXCEPTING CERTAIN AUDIT FINDINGS FROM FORMING
THE BASIS FOR RECOUPMENT; ADDING A PHARMACY BENEFITS MANAGER
OR ITS SUBCONTRACTOR AS AN AUDITING ENTITY.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:

SECTION 1. Section 61-11-18.2 NMSA 1978 (being Laws
2007, Chapter 15, Section 1) is amended to read:

"61-11-18.2. AUDIT OF PHARMACY RECORDS.--

A. An audit of the records of a pharmacy by an
entity shall be conducted in accordance with the following
criteria:

(1) the entity conducting the initial
on-site audit shall give the pharmacy notice at least two
weeks prior to conducting the initial on-site audit for each
audit cycle;

(2) an audit that involves clinical or
professional judgment shall be conducted by or in
consultation with a pharmacist;

(3) a clerical or recordkeeping error,
regarding a required document or record, shall not
necessarily constitute fraud, and that error:

(a) shall not be the basis for
recoupment unless the error results in overpayment to the

1 pharmacy, and any amount to be charged back or recouped due
2 to overpayment shall not exceed the amount the pharmacy was
3 overpaid; and

4 (b) shall not be subject to criminal
5 penalties without proof of intent to commit fraud;

6 (4) a pharmacy may use the records of a
7 hospital, physician or other authorized practitioner of the
8 healing arts for drugs or medicinal supplies written or
9 transmitted by any means of communication for purposes of
10 validating the pharmacy record with respect to orders or
11 refills of a dangerous drug or controlled substance;

12 (5) a finding of an overpayment or
13 underpayment shall be based on the actual overpayment or
14 underpayment of a specific individual claim;

15 (6) each pharmacy shall be audited under the
16 same standards and parameters as other similarly situated
17 pharmacies audited by the entity;

18 (7) a pharmacy shall be allowed at least
19 twenty-one business days, with reasonable extensions allowed,
20 following receipt of the preliminary audit report in which to
21 produce documentation to address any discrepancy found during
22 an audit;

23 (8) the period covered by an audit shall not
24 exceed two years from the date the claim was submitted to or
25 adjudicated by an entity, unless it conflicts with state or

1 federal law;

2 (9) an audit shall not be initiated or
3 scheduled during the first five calendar days of a month;

4 (10) the preliminary audit report shall be
5 delivered to the pharmacy within one hundred twenty days,
6 with reasonable extensions allowed, after conclusion of the
7 audit, and the final report shall be delivered to the
8 pharmacy within six months after receipt of the preliminary
9 audit report or final appeal, as provided for in Subsection B
10 of this section, whichever is later;

11 (11) notwithstanding any other provision in
12 this section, the entity conducting the audit shall not use
13 the accounting practice of extrapolation in calculating
14 recoupments or penalties for audits;

15 (12) the auditing entity conducting a
16 pharmacy audit shall not compensate an employee or contractor
17 with which an auditing entity contracts to conduct a pharmacy
18 audit based on the amount claimed or the actual amount
19 recouped from the pharmacy being audited;

20 (13) an entity shall not charge a fee for
21 conducting an on-site or a desk audit unless there is a
22 finding of actual fraud;

23 (14) as a result of an audit finding, a
24 pharmacist or pharmacy may resubmit a claim within twenty-one
25 business days to correct clerical or recordkeeping errors in

1 lieu of recoupment of a claim where no actual financial harm
2 to the patient has occurred; provided that the prescription
3 was dispensed according to prescription documentation
4 requirements pursuant to the Pharmacy Act;

5 (15) the requirements for a valid
6 prescription or a pharmacy benefits manager's required
7 operational standards for pharmacies shall not be more
8 stringent than federal or state requirements;

9 (16) with notice to the prescriber, a
10 pharmacy or pharmacist may satisfy state and federal
11 requirements for a valid prescription by affixing or writing
12 additional information on the front or back of a prescription
13 or if the required information is electronically recorded on
14 a patient's profile and is readily retrievable;

15 (17) the days' supply for unit-of-use items,
16 such as topicals, drops, vials and inhalants, shall not be
17 limited beyond manufacturer recommendations;

18 (18) if the only commercially available
19 package size exceeds an entity's maximum days' supply, the
20 dispensing of such package size must be accepted by the
21 entity and shall not be the basis for recoupment;

22 (19) if the only commercially available
23 package size exceeds an entity's maximum days' supply and the
24 entity accepts the refill of such prescription, the entity
25 shall not recoup such claim as an early refill; and

1 (20) the failure of a pharmacy to collect a
2 copayment shall not be the basis for recoupment if the
3 pharmacy provides documentation of billing of the claim and a
4 reasonable attempt to collect the copayment.

5 B. Recoupment of any disputed funds shall occur
6 after final internal disposition of the audit, including the
7 appeals process set forth in Subsection C of this section.
8 Should the identified discrepancy for an individual audit
9 exceed twenty-five thousand dollars (\$25,000), future
10 payments to the pharmacy may be withheld pending finalization
11 of the audit.

12 C. Each entity conducting an audit shall establish
13 an appeals process under which a pharmacy may appeal an
14 unfavorable preliminary audit report to the entity. If,
15 following the appeal, the entity finds that an unfavorable
16 audit report or any portion of the audit is unsubstantiated,
17 the entity shall dismiss the audit report or the
18 unsubstantiated portion of the report of the audit without
19 the necessity of any further proceedings.

20 D. This section does not apply to any
21 investigative audit that involves probable or potential
22 fraud, waste, abuse or willful misrepresentation.

23 E. In a wholesale invoice audit conducted by an
24 entity:

25 (1) an entity shall not audit the claims of

1 another entity;

2 (2) the following shall not form the basis
3 for recoupment:

4 (a) the national drug code for the
5 dispensed drug is in a quantity that is a sub-unit or
6 multiple of the purchased drug as reflected on a supporting
7 wholesale invoice;

8 (b) the correct quantity dispensed is
9 reflected on the audited pharmacy claim; or

10 (c) the drug dispensed by the pharmacy
11 on an audited pharmacy claim is identical to the strength and
12 dosage form of the drug purchased;

13 (3) the entity shall accept as evidence:

14 (a) supplier invoices issued prior to
15 the date of dispensing the drug underlying the audited claim;

16 (b) invoices from any supplier
17 authorized by law to transfer ownership of the drug acquired
18 by the audited pharmacy;

19 (c) copies of supplier invoices in the
20 possession of the audited pharmacy; and

21 (d) reports required by any state board
22 or agency; and

23 (4) within five business days of request by
24 the audited pharmacy, the entity shall provide supporting
25 documentation provided to the entity by the audited

1 pharmacy's suppliers.

2 F. As used in this section:

3 (1) "entity" means a managed care company,
4 insurance company or third-party payor, or representative of
5 a managed care company, insurance company or third-party
6 payor, or a pharmacy benefits manager or a subcontractor of a
7 pharmacy benefits manager; and

8 (2) "extrapolation" means a mathematical
9 process or technique used to estimate audit results or
10 findings for a larger batch or group of claims not reviewed."=